Hsbc Holdings PLC Purchases 21,919 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Hsbc Holdings PLC lifted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 59.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 58,589 shares of the company’s stock after buying an additional 21,919 shares during the quarter. Hsbc Holdings PLC owned about 0.10% of Harmony Biosciences worth $2,193,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Dimensional Fund Advisors LP grew its stake in Harmony Biosciences by 8.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,830,726 shares of the company’s stock valued at $68,507,000 after buying an additional 139,145 shares during the last quarter. American Century Companies Inc. lifted its position in Harmony Biosciences by 11.2% during the 3rd quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock worth $46,013,000 after acquiring an additional 168,145 shares during the last quarter. State Street Corp boosted its holdings in Harmony Biosciences by 0.5% during the fourth quarter. State Street Corp now owns 1,661,850 shares of the company’s stock valued at $62,186,000 after acquiring an additional 8,246 shares during the period. LSV Asset Management boosted its holdings in Harmony Biosciences by 3.9% during the fourth quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock valued at $62,008,000 after acquiring an additional 62,200 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Harmony Biosciences by 15.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,491,605 shares of the company’s stock valued at $55,816,000 after purchasing an additional 196,224 shares during the last quarter. 86.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

HRMY has been the subject of several research analyst reports. Truist Financial boosted their price objective on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. Zacks Research raised Harmony Biosciences from a “strong sell” rating to a “hold” rating in a report on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a research report on Wednesday, June 24th. Finally, Weiss Ratings upgraded Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, June 23rd. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $40.89.

Harmony Biosciences Trading Down 0.4%

Shares of HRMY opened at $35.34 on Tuesday. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.87. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. The stock has a 50 day simple moving average of $32.08 and a 200-day simple moving average of $32.91. The stock has a market cap of $2.05 billion, a PE ratio of 14.25, a PEG ratio of 0.25 and a beta of 0.96.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. During the same period in the prior year, the firm earned $0.78 EPS. Harmony Biosciences’s quarterly revenue was up 16.6% compared to the same quarter last year. On average, sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 3.2 EPS for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.